Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain drug
Biotech
Lexicon feels the pain as non-opioid data underwhelm investors
The biotech focused on low-dose results, rather than the overall primary endpoint miss, but investors took a much more downbeat view of the data.
Nick Paul Taylor
Mar 3, 2025 9:52am
Tris shows its opioid alternative is less likely to be abused
Jan 28, 2025 10:53am
Tris' opioid alternative reduces post-surgery pain in phase 3
Jan 22, 2025 8:30am
Vertex's pain prospect underwhelms versus placebo, sinking stock
Dec 19, 2024 7:41am
Novo Holdings-backed SiteOne charges up with $100M financing
Dec 18, 2024 7:00am
Vertex's phase 3 pain trials hit goals but fail to beat Vicodin
Jan 30, 2024 8:00am